Inhibitors alter the spectrum and redox properties of monoamine oxidase A

被引:21
作者
Ramsay, RR [1 ]
Hunter, DJB [1 ]
机构
[1] Univ St Andrews, Ctr Biomol Sci, St Andrews KY16 9AL, Fife, Scotland
来源
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS | 2002年 / 1601卷 / 02期
关键词
amphetamine; harmine; pirlindole; befloxatone; flavin-inhibitor stacking; semiquinone stabilisation;
D O I
10.1016/S1570-9639(02)00466-1
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Monoamine oxidase A (MAO A) catalyses the oxidation of both neurotransmitter and ingested amines. The mechanism of catalysis involves the covalently bound FAD cofactor. Although substrates and inhibitors alter the thermodynamic and kinetic properties of the flavin, how the ligands interact with the flavin is unknown. This work characterises the spectral changes that occur on inhibitor binding to MAO A and examines how the binding influences the flavin. The inhibitors, D-amphetamine, harmine, tetrindole, and befloxatone all induce similar (but not identical) changes in the spectrum of MAO A, consistent with stacking of inhibitor with the flavin in the active site. D-Amphetamine, harmine, and tetrindole stabilise the semiquinone form of FAD during reduction of MAO A by dithionite and no further reduction of these inhibitor-MAO A complexes has been observed. In contrast, semiquinone is never observed during reduction of the befloxatone-MAO A complex. Instead, partial reduction directly to the FADH, form occurs extremely slowly. Thus, inhibitor binding has a strong, structure-dependent influence on the environment of the flavin that alters its electronic properties. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:178 / 184
页数:7
相关论文
共 20 条
[1]   Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders [J].
Binda, C ;
Newton-Vinson, P ;
Hubálek, F ;
Edmondson, DE ;
Mattevi, A .
NATURE STRUCTURAL BIOLOGY, 2002, 9 (01) :22-26
[2]   Modulation of flavin recognition and redox properties through donor atom-π interactions [J].
Breinlinger, EC ;
Keenan, CJ ;
Rotello, VM .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1998, 120 (34) :8606-8609
[3]   SPECTROSCOPIC STUDY OF MOLECULAR ASSOCIATIONS BETWEEN RIBOFLAVIN AND SOME BETA-CARBOLINE DERIVATIVES [J].
CODONER, A ;
MONZO, IS ;
ORTIZ, C ;
OLBA, A .
JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 2, 1989, (02) :107-111
[4]  
Curet O, 1996, J PHARMACOL EXP THER, V277, P253
[5]   MOLECULAR DETERMINANTS IN THE BIOACTIVATION OF THE DOPAMINERGIC NEUROTOXIN N-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE (MPTP) [J].
EFANGE, SMN ;
BOUDREAU, RJ .
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 1991, 5 (05) :405-417
[6]   SELECTIVE INHIBITORS OF MONOAMINE-OXIDASE (MAO-A AND MAO-B) AS PROBES OF ITS CATALYTIC SITE AND MECHANISM [J].
KALGUTKAR, AS ;
CASTAGNOLI, N ;
TESTA, B .
MEDICINAL RESEARCH REVIEWS, 1995, 15 (04) :325-388
[7]   Inhibition of monoamine oxidase A by beta-carboline derivatives [J].
Kim, H ;
Sablin, SO ;
Ramsay, RR .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1997, 337 (01) :137-142
[8]  
Medvedev A. E., 1999, Neurobiology (Budapest), V7, P151
[9]   QSAR analysis of indole analogues as monoamine oxidase inhibitors [J].
Medvedev, AE ;
Ivanov, AS ;
Veselovsky, AV ;
Skvortsov, VS ;
Archakov, AI .
JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES, 1996, 36 (04) :664-671
[10]   A REVERSIBLE MONOAMINE-OXIDASE INHIBITOR TOLOXATONE - COMPARISON OF ITS PHYSICOCHEMICAL PROPERTIES WITH THOSE OF OTHER INHIBITORS INCLUDING BROFAROMINE, HARMINE, R40519 AND MOCLOBEMIDE [J].
MOUREAU, F ;
WOUTERS, J ;
DEPAS, M ;
VERCAUTEREN, DP ;
DURANT, F ;
DUCREY, F ;
KOENIG, JJ ;
JARREAU, FX .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 1995, 30 (11) :823-838